EyePoint Pharmaceuticals (EYPT) AI Stock Analysis

• Market Cap: $1.19B
• Dividend Yield: N/A
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -7.38%
• EPS Growth: -49.03%
• Country: US
• Employees: 165
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.85
• Shares Outstanding: 82,787,220
• 10 Day Avg. Volume: 1,250,761
• 30 Day Avg. Volume: 1,499,976
• PEG Ratio: -0.12
• Price to Book (P/B): 1.25
• Price to Sales (P/S): 9.69
• P/FCF Ratio: -3.22
• Enterprise Value/Market Cap: 0.69
• Enterprise Value/Revenue: 19.33
• Enterprise Value/Gross Profit: 20.55
• Enterprise Value/Ebitda: -3.90
• 1Y Price Target: $31.60
• Price Target Upside: 119.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -3.03
• Revenue Forecast (FY): $31.80M

• Rating: 52 Neutral
• Price Target: $13.50 ▼(-6.25% Downside)

EyePoint Pharmaceuticals' overall stock score reflects its significant financial challenges and unprofitability, offset by strong clinical progress and a solid cash position. The company's strategic focus on innovative treatments and potential market leadership in the biotechnology sector are positive indicators, but financial improvements are crucial for long-term success.

Positive Factors

Strong Financial Position

A robust cash position ensures EyePoint can fund operations into Q4 2027, providing stability and supporting long-term strategic initiatives.

Clinical Program Advancements

Successful trial enrollments position EyePoint for potential market leadership in wet AMD treatment, enhancing its competitive edge.

Innovative Drug Mechanism

The multi-mechanism action of DURAVYU supports its effectiveness in treating multifactorial diseases, strengthening EyePoint's product portfolio.

Negative Factors

Declining Revenue

Significant revenue decline indicates challenges in maintaining sales momentum, potentially impacting long-term financial health.

Increased Operating Expenses

Rising operating expenses, mainly due to clinical trial costs, could strain profitability and cash flow if not managed effectively.

Net Loss Increase

The widening net loss reflects ongoing profitability challenges, necessitating strategic improvements in cost management and revenue generation.

EyePoint Pharmaceuticals Business Overview & Revenue Model

Company Description

EyePoint Pharmaceuticals (EYPT) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for diseases of the eye. The company specializes in its proprietary drug delivery technologies, which are designed to enhance the effectiveness of ophthalmic treatments. EyePoint's core product offerings include products for the treatment of retinal diseases and other serious eye conditions, leveraging its platform to provide sustained delivery of medication, thus improving patient outcomes.

How the Company Makes Money

EyePoint Pharmaceuticals generates revenue primarily through the sale of its marketed products, which include therapeutics for eye diseases. The company also benefits from partnerships and collaborations with other pharmaceutical companies, which may involve licensing agreements, co-development deals, or royalties on sales of products that utilize EyePoint's proprietary technologies. Additionally, financial support from government grants and research funding can contribute to its revenue streams. The success of its products in the market, along with strategic alliances, plays a crucial role in driving the company's overall earnings.

EyePoint Pharmaceuticals Financial Statement Overview

Summary

EyePoint Pharmaceuticals faces significant financial challenges, with declining revenues and persistent losses impacting profitability. Despite a strong gross profit margin and low leverage, negative cash flows and returns on equity highlight operational inefficiencies. The company needs strategic improvements in cost management and revenue generation.

Income Statement

EyePoint Pharmaceuticals shows a declining revenue trend with a negative revenue growth rate of -18.42% in the TTM. The gross profit margin remains strong at 94.08%, indicating efficient cost management. However, the company struggles with profitability, evidenced by a significant negative net profit margin of -485.95% and negative EBIT and EBITDA margins. This suggests challenges in managing operating expenses and achieving profitability.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.11, indicating conservative leverage. However, the return on equity is negative at -76.13%, reflecting ongoing losses and inefficiencies in generating returns for shareholders. The equity ratio stands at 79.52%, showing a strong equity base relative to total assets, which provides some stability.

Cash Flow

EyePoint Pharmaceuticals faces cash flow challenges with a negative operating cash flow and free cash flow. The free cash flow growth rate is positive at 10.08%, but the operating cash flow to net income ratio is negative, indicating cash flow issues relative to reported losses. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow aligns with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.34M	43.27M	46.02M	41.40M	36.94M	34.44M
Gross Profit	39.83M	39.56M	41.39M	33.08M	28.76M	28.61M
EBITDA	-210.01M	-129.23M	-69.00M	-96.62M	-50.15M	-35.49M
Net Income	-205.75M	-130.87M	-70.80M	-102.25M	-58.42M	-45.39M
Balance Sheet
Total Assets	251.69M	418.46M	355.18M	180.36M	263.37M	91.72M
Cash, Cash Equivalents and Short-Term Investments	204.02M	370.91M	331.05M	144.56M	211.56M	44.91M
Total Debt	21.30M	21.86M	4.91M	46.35M	39.20M	40.99M
Total Liabilities	51.51M	81.96M	88.86M	83.99M	78.99M	73.18M
Stockholders Equity	200.18M	336.50M	266.32M	96.37M	184.38M	18.54M
Cash Flow
Free Cash Flow	-213.59M	-130.28M	-1.61M	-67.16M	-50.25M	-14.80M
Operating Cash Flow	-210.91M	-126.23M	1.88M	-65.00M	-50.10M	-14.44M
Investing Cash Flow	47.28M	-219.35M	-3.31M	-17.27M	-33.12M	-362.00K
Financing Cash Flow	158.38M	164.02M	187.07M	-690.00K	216.90M	37.49M

EyePoint Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EYPT, the sentiment is Positive. The current price of 14.4 is above the 20-day moving average (MA) of 12.43, above the 50-day MA of 12.80, and above the 200-day MA of 9.38, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 64.12 is Neutral, neither overbought nor oversold. The STOCH value of 77.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EYPT.

EyePoint Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAR	70 Outperform	$1.16B	1,223.61	0.44%	―	26.54%	―
STOK	60 Neutral	$1.73B	45.98	15.02%	―	1128.17%	―
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
URGN	55 Neutral	$1.21B	―	―	―	8.00%	-10.15%
EYPT	52 Neutral	$1.19B	―	-98.23%	―	-7.38%	-49.03%
TNGX	51 Neutral	$1.39B	―	-51.65%	―	53.28%	21.77%
MGTX	44 Neutral	$609.32M	―	-611.42%	―	96.83%	-61.92%

EyePoint Pharmaceuticals Corporate Events

EyePoint Pharmaceuticals Files $200M Stock Offering Prospectus

On November 6, 2025, EyePoint Pharmaceuticals filed a prospectus supplement to its registration statement with the SEC, enabling a registered offering of up to $200 million in common stock. This move, under the Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., signifies a strategic financial maneuver to potentially enhance the company’s capital, impacting its market positioning and stakeholder interests.

The most recent analyst rating on (EYPT) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

EyePoint Pharma Advances DURAVYU in Retinal Disease Trials

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing innovative therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, in advanced clinical trials for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).

EyePoint Pharma’s Earnings Call: Strategic Gains Amid Financial Hurdles

EyePoint Pharma’s recent earnings call painted a picture of both challenges and strategic progress. While the company faced financial hurdles with decreased revenue and increased operating expenses, it demonstrated strong clinical advancements and maintained a robust financial position. This dual narrative suggests that EyePoint is poised for future growth despite current setbacks.

EyePoint Pharma’s DEXYCU Study: A Potential Game-Changer in Pediatric Cataract Treatment

EyePoint Pharmaceuticals is conducting a Phase 3/4 clinical study titled ‘A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract.’ The study aims to assess the safety of DEXYCU, a dexamethasone intraocular suspension, in treating inflammation after ocular surgery in children with cataracts, a significant concern in pediatric ophthalmology.

EyePoint Pharmaceuticals Raises $141M in Public Offering

On October 14, 2025, EyePoint Pharmaceuticals announced an underwritten public offering of 11,000,000 shares of its common stock and pre-funded warrants for 1,500,000 shares, raising approximately $141 million. The offering, which closed on October 16, 2025, aims to fund the clinical development of DURAVYU™ and support pipeline initiatives. This move is expected to bolster EyePoint’s financial position and advance its strategic objectives in the biopharmaceutical industry.

The most recent analyst rating on (EYPT) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.

EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program

On October 14, 2025, EyePoint Pharmaceuticals announced the initiation of its pivotal Phase 3 program for DURAVYU, targeting diabetic macular edema (DME), with first patient dosing expected in Q1 2026. The program follows a non-inferiority approval pathway and includes two trials, COMO and CAPRI, each enrolling approximately 240 patients. New preclinical data highlights DURAVYU’s potential as a multi-mechanism treatment, inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, which are key contributors to DME and wet AMD. This advancement positions DURAVYU as a promising option for addressing the multifactorial nature of DME and reducing treatment burdens for patients.

The most recent analyst rating on (EYPT) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.